Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse of Hematological Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT07014449
What this trial is testing

Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
AML (Acute Myelogenous LeukemiaRelapsed Acute Myelogenous LeukemiaRefractory Acute Myeloid Leukemia+3 more
Hangzhou Weben Pharma Co., Ltd 18
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07107204
What this trial is testing

A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Relapsed or Refractory Hematologic MalignanciesLeukemiaLymphoma+1 more
Biotroy Therapeutics 116
Early research (Phase 1)Study completedNCT01822509
What this trial is testing

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

Who this might be right for
Allogeneic Hematopoietic Stem Cell Transplant RecipientMyeloproliferative NeoplasmRecurrent Acute Lymphoblastic Leukemia+8 more
National Cancer Institute (NCI) 71
Early research (Phase 1)Study completedNCT00825487
What this trial is testing

Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies

Who this might be right for
Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 50
Very early researchLooking for participantsNCT04283006
What this trial is testing

CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

Who this might be right for
Relapsed and RefractoryLymphoid Hematological Malignancies
He Huang 100
Testing effectiveness (Phase 2)UnknownNCT03091933
What this trial is testing

Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)

Who this might be right for
Hematologic CancerRelapse LeukemiaRelapsed Adult ALL+6 more
Ciusss de L'Est de l'Île de Montréal 20
Testing effectiveness (Phase 2)Ended earlyNCT02433483
What this trial is testing

Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients

Who this might be right for
Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
St. Jude Children's Research Hospital 4
Testing effectiveness (Phase 2)Study completedNCT00054327
What this trial is testing

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Who this might be right for
LeukemiaLymphomaMyelodysplastic Syndromes+1 more
Case Comprehensive Cancer Center 34
Early research (Phase 1)UnknownNCT05528887
What this trial is testing

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

Who this might be right for
Relapsed/Refractory Hematological MalignanciesLymphomaMyeloma+1 more
The Affiliated People's Hospital of Ningbo University 10
Testing effectiveness (Phase 2)Looking for participantsNCT05908409
What this trial is testing

IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies

Who this might be right for
Multiple Myeloma (MM)Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedDouble Hit Lymphoma+3 more
IDP Discovery Pharma S.L. 37
Early research (Phase 1)Ended earlyNCT04553692
What this trial is testing

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

Who this might be right for
Solid TumorColorectal CancerNon Hodgkin Lymphoma+5 more
IGM Biosciences, Inc. 272
Testing effectiveness (Phase 2)Study completedNCT00004907
What this trial is testing

Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Northwestern University
Not applicableNot Yet RecruitingNCT07345780
What this trial is testing

Clinical Study on the Safety and Efficacy of CD7-Targeted Chimeric Antigen Receptor (CAR) Gene-Modified T Cells for the Treatment of CD7-Positive Hematological Malignancies

Who this might be right for
CD7-Positive Hematological Malignancies
Donghua Zhang 28
Testing effectiveness (Phase 2)Study completedNCT00619645
What this trial is testing

Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more
University of California, Davis 8
Early research (Phase 1)Study completedNCT00049686
What this trial is testing

VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome

Who this might be right for
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
Vion Pharmaceuticals
Not applicableStudy completedNCT00956475
What this trial is testing

Quality of Life in Younger Leukemia and Lymphoma Survivors

Who this might be right for
Anxiety DisorderCancer SurvivorFatigue+7 more
Case Comprehensive Cancer Center 48
Very early researchUnknownNCT04156256
What this trial is testing

CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Who this might be right for
Hematologic MalignancyAcute Myeloid LeukemiaMyelodysplastic Syndromes+2 more
iCell Gene Therapeutics 20
Testing effectiveness (Phase 2)Looking for participantsNCT04588922
What this trial is testing

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Who this might be right for
Hematologic Malignancies
Sellas Life Sciences Group 160
Testing effectiveness (Phase 2)Looking for participantsNCT05110742
What this trial is testing

Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances

Who this might be right for
Hematological Malignancy
M.D. Anderson Cancer Center 64
Not applicableStudy completedNCT00993694
What this trial is testing

Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+6 more
Vanderbilt University 41
Next Page